




[Figure 1]




[Figure 2A]




[Figure 2B]



[Figure 2C]




[Figure 2D]




4/29

[Figure 2E]




[Figure 3]




6/29

[Figure 4A]




[Figure 4B]




7/29

[Figure 4C]




[Figure 4D]




8/29

[Figure 5]




9/29

[Figure 6]




10/29

[Figure 7A]




[Figure 7B]




11/29

[Figure 7C]




[Figure 7D]




12/29


[Figure 8]



[Figure 9A]




[Figure 9B]




14/29

[Figure 10A]



[Figure 10B]



15/29

[Figure 11A]

SEQ ID No: 1 wildtype human IgG1 (G1m17) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSSGLYSLSSVTPPSSSLGT
QTYICNVNHKPSNTKVDKKEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSSV
MHEALHNHYTQKSLSLSPGK

[Figure 11B]

SEQ ID No: 2 wildtype human IgG1 (G1m3) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSSGLYSLSSVTPPSSSLGT
QTYICNVNHKPSNTKVDKRVKPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSSV
MHEALHNHYTQKSLSLSPGK

[Figure 11C]

SEQ ID No: 3 wildtype human IgG4 constant region

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSSGLYSLSSVTPPSSSLGT
KTYTCNVNHNKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQF
NWNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLTP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFCSSVMHE
ALHNHYTQKSLSLGLK

16/29

[Figure 12A]

SEQ ID No: 4 LALA-DG variant of human IgG1 (G1m17) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVPSSSLGT
QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVGVSHPEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSV
MHEALHNHYTQKSLSLSPGK

[Figure 12B]

SEQ ID No: 5 LALA-DG variant of human IgG1 (G1m3) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVPSSSLGT
QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVGVSHPEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSV
MHEALHNHYTQKSLSLSPGK

17/29

[Figure 13A]

SEQ ID No: 6 LALA-DN variant of human IgG1 (G1m17) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGGSVFLFPPKPKDTLMISRTPEVTCVIVVNVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSV
MHEALHNHYTQKSLSLSPGK

[Figure 13B]

SEQ ID No: 7 LALA-DN variant of human IgG1 (G1m3) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKRVKVEPKSCDKTHTCPPCPAPEAAGGGSVFLFPPKPKDTLMISRTPEVTCVIVVNVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSV
MHEALHNHYTQKSLSLSPGK

18/29

[Figure 14A]

SEQ ID No: 8 LALA-DGPA variant of human IgG1(G1m17) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSKVHTFPVLQSSGLYSLSSVTPVSSSLGT
QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGGSVFLFPPKPKDTLMISRTPEVTCVVGVSHPEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSV
MHEALHNHYTQKSLSLSPGK

[Figure 14B]

SEQ ID No: 9 LALA-DGPA variant of human IgG1(G1m3) constant region

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSKVHTFPVLQSSGLYSLSSVTPVSSSLGT
QTYICNVNHKPSNTKVDKRVKVEPKSCDKTHTCPPCPAPEAAGGGSVFLFPPKPKDTLMISRTPEVTCVVGVSHPEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSV
MHEALHNHYTQKSLSLSPGK

19/29

[Figure 15A]

SEQ ID No: 10 FALA-DG variant of human IgG4 constant region

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTPSSSLGT
KTYTCNVDPKPSNTKVDKRVESKYGPPCPSCAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVGVSQEDPEVQF
NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLTP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVME
ALHNHYTQKSLSLGLK

[Figure 15B]

SEQ ID No: 11 FALA-DN variant of human IgG4 constant region

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTPSSSLGT
KTYTCNVDPKPSNTKVDKRVESKYGPPCPSCAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVGVSQEDPEVQF
NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLTP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVME
ALHNHYTQKSLSLGLK

[Figure 15C]

SEQ ID No: 12 FALA-DGPA variant of human IgG4 constant region

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTPSSSLGT
KTYTCNVDPKPSNTKVDKRVESKYGPPCPSCAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVGVSQEDPEVQF
NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLASSIEKTIKAKGQPREPQVYTLTP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVME
ALHNHYTQKSLSLGLK

20/29

[Figure 16A]

SEQ ID No: 13 Light chain of anti-EGFR antibody, panitumumab, IgG1 WT

DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISS
LQPEDIATYFCQHFHDLPLAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
QSGNSQESVTEQDSKSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[Figure 16B]

SEQ ID No: 14 Heavy chain of anti-EGFR antibody, panitumumab, IgG1 WT

QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKLEWIGHIYYSGNTNYPNPSLKSRLTISIDTSK
TQFSLKLSSVTAADTAIYYCVRDRVTAFAFDIWGGGTMTVSSASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGK

21/29

[Figure 17A]

SEQ ID No: 15 Light chain of LALA variant of anti-CD70 antibody, vorsetuzumab
DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTL
TISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[Figure 17B]

SEQ ID No: 16 Heavy chain of LALA variant of anti-CD70 antibody vorsetuzumab
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSIS
TAYMELSRLRSDDTAVYYCARDYGDYGM DYWGQGT TTVSSASTKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRV EPKSCDKTHTCPPCPA
PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
LHQQDLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSV MHEALHNHYTQKSLSLSPGK

22/29

[Figure 18A]

SEQ ID No: 17 Light chain of anti-LPS antibody, 011-1111, IgG1 WT

DIVMTQSPDSLAVSLGERATINCKASENVGNSVSWYQQKPGQPPKLLIYGASNRYTGVPDRFSGSGSGTDFTLTISS
LQAEDVAVYYCGQSYSPYTFGQGKTVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
QSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[Figure 18B]

SEQ ID No: 18 Heavy chain of anti-LPS antibody, 011-1111, IgG1 WT

QVQLVQSGAEVKKPGASVKVSCKASGYFTSYWINWVRQAPGGGLEWMGNIYPGSSSINYNEKFKSRVTITADTSTS
TAYMELSSLRSEDTAVYYCARTIYNYGSSGYNAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH
TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

23/29

[Figure 19A]

SEQ ID No: 19 human Fc γ RI

MWFLTLLLVVPVDGQVDTTKAVITLQPPWVSFQEETVTLHCEVLHLP
GSSTQWFLNGTATQTSTPSYRITSASVN
DSGEYRCQRGLSGRSDPIQLEIHRGWLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYRNGKAFKFFHWSNLTI
LKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLQRPGLQLYFSFYMGSK
TLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLRSPLELQVLGLQLPTPVWFHVLFYLA
VGIMFLVNTVLWVT
IRKELKRKKKWDLEISLDSGHEKKV
ISSLQEDRHLEELKCQEKEEQLEQEGVHRKEPQGAT

[Figure 19B]

SEQ ID No: 20 human Fc γ RIIa (R167)

MAMETQMSQNVCPNRLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARS
PESDSIQWFHN
GNLIPHTHTQPSYRFKANNNDSGEYTCQTGQTS
SDPVHLTVLSEWLVLTQPHLEFQEGETIMLRCHSWKDKPLVKVTF
FQNGKSQKF
SRLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGI
IVAVVIATAVAAIVAA
VVALIYCRKKRISANSTDPVKAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNI
YLTLPNDH
VNSNN

[Figure 19C]

SEQ ID No: 21 human Fc γ RIIa (H167)

MTMETQMSQNVCPNRLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARS
PESDSIQWFHN
GNLIPHTHTQPSYRFKANNNDSGEYTCQTGQTS
SDPVHLTVLSEWLVLTQPHLEFQEGETIMLRCHSWKDKPLVKVTF
FQNGKSQKF
SHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGI
IVAVVIATAVAAIVAA
VVALIYCRKKRISANSTDPVKAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNI
YLTLPNDH
VNSNN

[Figure 19D]

SEQ ID No: 22 human Fc γ RIIb/c

24/29

MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWINVLQEDSVTLTCRGTHSPE
SDSIQWFHNGNLIPHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWK
DKPLVKVTFQNGKSKKFSRSDPNFSIPQANSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAV
AAIVAAVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAEENTITYSLLMHPDALEEPDDQNR

[Figure 19E]

SEQ ID No: 23 human Fc γ R1IIa

MWQLLLPTALLLVSA^{GMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCGGAYSPEDNSTQWFHNESL}ISSQASSYFIDA
ATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSD
FYIPKATLKDSGSYFCRGLVGSKNVSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI
R
SSTRDWKDHKFKWRKDPQDK

[Figure 19F]

SEQ ID No: 24 human Fc γ R1IIb

MWQLLLPTALLLVSA^{GMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCGGAYSPEDNSTQWFHNESL}ISSQASSYFIDA
ATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSD
FHIPKATLKDSGSYFCRGLVGSKNVSETVNITITQGLAVSTISSFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI

25/29

[Figure 20A]

SEQ ID No: 25 cynomolgus Fc γ RI

MWFLTALLLVPVDGQVDTTKAVITLQPPWVSVFQEETVTLQCEVPRLPGSSSTQWFLNGTATQTSTPSYRITSASVK
DSGEYRCQRGPSGRSDPIQLEIHRDWLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYQNGKAFKFFYRNSQLTIL
KTNISHNGAYHCSGMGKHRYTSAGVSVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLQRPGLQLYFSFYMGSK
TLRGRNTSSEYQILTARREDSGFYWCEATTEDGNVLKRSELELQVLGLQLPTPVWLHVLFYLVVGIMVLVNTGLWVT
IRKELKRKKKWNLEISLDSAHEKKVTSSLQEDRHLEELKSQEKEQELQEGVHRKEPEEAK

[Figure 20B]

SEQ ID No: 26 cynomolgus Fc γ RIIa

MSQNVCPGNLWLLQPLTVLLLLASADSQTAPPKAVLKLEPPWINVLREDSVTLTCGGAHSPDSDSTQWFHNGNRIPTH
TQPSYRFKANNNDSGEYRCQTGRISLSDPVHLLTVLSEWLALQTPHLEFREGETIMLRCHSWKDKPLIKVTFFQNGIAK
KFSHMDPNFISIPQANHSHSGDYHCTGNIGYTPYSSKPVITITVQVPSVGSSSPMGIIIVAVVTGIAVAAIIVAAVVALIYC
RKKRISANSTDPVKAARFEPLGRQTIALRKRQLEETNNDYETADGGYMTLNPRAPTDDDRNIYLTSPNDYDNSNN

[Figure 20C]

SEQ ID No: 27 cynomolgus Fc γ RIIb

MGILSFLPVLATESDWADCKSSQPWGHMLLWTAFLAPVAGTPAAPPKAVLKLEPPWINVLREDSVTLTCGGAHSPD
SDSTQWFHNGNLIPHTHTQPSYRFKANNNDSGEYRCQTGRISLSDPVHLLTVLSEWLALQTPHLEFREGETILLRCHSWK
DKPLIKVTFFQNGISKKFSHMNPFSIPQANHSHSGDYHCTGNIGYTPYSSKPVITITVQVPSMGSSSPIGIIIVAVVTG
IIVAAIIVAAVVALIYCRKKRISANPTNPDEADKVAENTITYSLLMHPDALEEDDQNRV

[Figure 20D]

SEQ ID No: 28 cynomolgus Fc γ RIII

MWQLLLPTALLLVSAGMRAEDLPRAVVFLEPQWYRVLEKDRVTLKCGGAYSPEDNSTRWFHNESLISSQTSSYFIAA
ARVNNSGEYRCQTSLSLSDPVQLEVHIGWLLQAPRWVFKEEESIHLRCHSWKNTLLHKVTYLNQNGKGRKYFHQNSD

26/29

FYIPKATLKDSGSYFCRGLIGSKNVSETVNITITQDLAVSSISSFFPPGYQVSFCLVMVLLFAVDTGLYFSMKKSIP

SSTRDWEDHKFKWSKDPQDK

27/29

[Figure 21]

SEQ ID No: 29 human FcRn large receptor subunit p51

MGVPRQPWALGLLLFLLPGSLGAESHL SLLYHLTAVSSPAGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWEN
QVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPE
ALAI SQRWQQQDKAANKELTFLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFPPELQLR
FLRNGLAAGTGQGDGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLT
AAVGGALLWRRMRSGLPAPWISLRGDDTGVLPTPGEAQDADLKDVNVIPATA

28/29

[Figure 22]

SEQ ID No: 30 β 2 microglobulin

MSRSVALAVLALLSLSGLEAIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSK

DWSFYLLYYTEFTPTEKDEYACRVNHVTLSPKIVKWRDM

29/29

[Figure 23]

SEQ ID No: 31 human Fc γ RIIIa (V176F)

MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCGAYSPEDNSTQWFHNESLISSQASSYFIDA
ATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSD
FYIPKATLKDSGSYFCRGLFGSKNVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI
RSSTRDWKDHKFKWRKDPQDK